Capricor Therapeutics Inc (CAPR) Reports Encouraging Year-End Financials and Advances in DMD Therapy
-
Revenue Growth: Q4 revenue soared to $12.1 million, a significant increase from $1.0 million in Q4 2022.
-
Reduced Net Loss: Q4 net loss narrowed to $0.8 million ($0.02 per share), improving from a net loss of $7.7 million ($0.31 per share) in the prior year.
-
Operating Expenses: Increased to $13.2 million in Q4 2023 from $9.0 million in Q4 2022, reflecting investment in research and development.
-
Cash Position: Ended the year with $39.5 million in cash, cash equivalents, and marketable securities.
-
Strategic Partnerships: Collaboration with Nippon Shinyaku and NIH for CAP-1002 and exosome-based vaccine development.
-
Financial Outlook: Funds expected to cover expenses into Q1 2025, excluding potential milestone payments and strategic capital uses.
On February 29, 2024, Capricor Therapeutics Inc (NASDAQ:CAPR) released its 8-K filing, detailing the financial results for the fourth quarter and full year ended December 31, 2023, and providing a corporate update. The United States-based biotechnology company, which focuses on the discovery, development, and commercialization of first-in-class biological therapies, has made significant strides in its Duchenne muscular dystrophy (DMD) program and its exosome-based vaccine initiatives.
Financial Performance and Corporate Milestones
Capricor reported a substantial increase in revenue for the fourth quarter of 2023, reaching approximately $12.1 million, up from $1.0 million in the same period of the previous year. This growth is attributed to the ratable recognition of payments from its U.S. Commercialization and Distribution Agreement with Nippon Shinyaku. Despite increased operating expenses, which totaled approximately $13.2 million for the quarter due to heightened research and development activities, the company managed to reduce its net loss to $0.8 million, or $0.02 per share, compared to a net loss of $7.7 million, or $0.31 per share, in the fourth quarter of 2022.
The company's cash position remains strong, with cash, cash equivalents, and marketable securities totaling approximately $39.5 million as of December 31, 2023. This financial stability is expected to support Capricor's operations into the first quarter of 2025, not accounting for any additional potential milestone payments or strategic capital uses.
Advancements in DMD Treatment and Exosome Technology
Capricor's lead product candidate, CAP-1002, is advancing through Phase 3 clinical development for the treatment of DMD. The company completed enrollment for Cohort A of the Phase 3 HOPE-3 pivotal trial and reported a successful interim futility analysis. CAP-1002 has received Orphan Drug Designation and RMAT (Regenerative Medicine Advanced Therapy Designation), and if approved by the FDA, Capricor could receive a Priority Review Voucher (PRV).